STRIDES AND PFIZER STRENGTHEN PARTNERSHIP

STRIDES AND PFIZER STRENGTHEN PARTNERSHIP
ONCOLOGY AGREEMENT EXTENDED TO EUROPE, CANADA, AUSTRALIA,
NEW ZEALAND, JAPAN AND KOREA
AGREEMENT FOR NICHE STERILE INJECTABLES FOR THE US MARKET
New York/Bangalore, May 13, 2010: Strengthening the collaboration announced earlier this
year, Strides Arcolab (BSE: 532531, NSE: STAR) today announced the signing of two licensing
and supply agreements with Pfizer Inc. (NYSE: PFE) to address new markets and product
segments. Under the first agreement, Strides will license and supply up to 38 generic oncology
products to Pfizer for markets in the European Union, Canada, Australia, New Zealand, Japan,
and Korea. The second agreement covers niche sterile injectables for the U.S. market. The
finished dosage form products will be commercialized by Pfizer through its Established Products
Business Unit. The financial terms of both agreements were not disclosed.
"We are excited about extending our important partnership with Strides to reach an even larger
global patient population," said David Simmons, president and general manager of Pfizer's
Established Products Business Unit. "This continued collaboration also reinforces our
commitment to become a leader in the injectables market."
The new agreements follow an agreement between Pfizer and Strides Arcolab announced in
January 2010 to deliver 40 generic products, many of which are oncology therapeutics, to
healthcare providers and patients in the United States. With the agreements signed today, the
collaboration between Pfizer and Strides Arcolab now extends to a total of 45 products
addressing countries around the globe.
Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore - 560076, India
BSE: 532531
NSE: STAR
Press Release
Friday, May 14, 2010
"We are delighted to strengthen our engagement - it validates our strategic intent to be a partner
of choice to Pfizer and to be a leader in the specialty segment with a focus on specific therapeutic
segments such as oncology," said Arun Kumar, Vice Chairman and Group CEO.
Under the new agreements, the first of the products is expected to be commercialized in late
2010/early 2011.
Pfizer's Established Products Business Unit launched its U.S. Injectables team about a year ago
and is already marketing products in the United States. Through this collaboration with Strides,
Pfizer continues to demonstrate its commitment to become one of the top players in the
injectables market.
Strides Arcolab Limited: Leadership through Partnering
Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock
Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in
Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical
products with an emphasis on sterile injectables.
The company has 14 manufacturing facilities across 6 countries and has a presence in more than
75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-
scientist strong global R&D Centre located in Bangalore. Additional information is available at
the company's website at www.stridesarco.com.
For further information, please contact:
Strides
Mr. Arun Kumar, Vice Chairman & Group CEO
+91 80 66580118
Mr. Kannan. N (Investors)
+91 80 66580751
Melissa Arulappan (Media)
+91 98450 22389
PR Consultancy
Mahesh Nair, Corporate Voice/Weber Shandwick
+91 9880376648
[email protected]
Kasturi Wasmatkar
+91 9916728393
[email protected]

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.